Recent developments concerning Eli Lilly & Company (LLY) have caught our attention. Our last reviews of LLY were conducted on April 9, 2024, and August 16, 2023, when the stock prices were $777.29 and $546.62, respectively. At those times, LLY was highly ranked in the Favored Green Zone of the SIA S&P 100 Index Report, reflecting its strong performance and leadership position. The stock had surged from just over $150 in 2021 to as high as $950. However, recent data suggest a shift. LLY is now showing signs of weakness, with our primary indicator—relative strength—issuing its first sell signal for the stock in years.